Next Science Limited (NXS-ASX)NXS is commercialising its Xbio technology platform to disrupt biofilm structures that are integral to myriad bacterial infections. Several product approvals and distribution agreements are in place in the US market, with several more to come in CY20, in addition to pending approvals for the European market. NXS has a unique position in addressing antibiotic resistance, with several products having blockbuster potential. We believe CY20 is an important year in the commercial development of NXS which should drive investor sentiment.
https://www.livewiremarkets.com/wires/16-top-australian-stock-picks
NXS in Canncord Genuity's top 16 picks
Add NXS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.010(4.44%) |
Mkt cap ! $68.54M | |||
| Open | High | Low | Value | Volume |
| 22.0¢ | 23.5¢ | 21.5¢ | $46.14K | 206.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 130676 | 21.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 19533 | 2 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| NXS (ASX) Chart |